- Home
- FLYE vs MGNX Comparison
FLYE vs MGNX Comparison
Compare FLYE & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLYE
- MGNX
- Stock Information
- Founded
- FLYE 2018
- MGNX 2000
- Country
- FLYE United States
- MGNX United States
- Employees
- FLYE N/A
- MGNX N/A
- Industry
- FLYE Aerospace
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- FLYE Industrials
- MGNX Health Care
- Exchange
- FLYE Nasdaq
- MGNX Nasdaq
- Market Cap
- FLYE 91.6M
- MGNX 99.7M
- IPO Year
- FLYE 2024
- MGNX 2013
- Fundamental
- Price
- FLYE $0.56
- MGNX $1.61
- Analyst Decision
- FLYE
- MGNX Hold
- Analyst Count
- FLYE 0
- MGNX 6
- Target Price
- FLYE N/A
- MGNX $3.20
- AVG Volume (30 Days)
- FLYE 636.1K
- MGNX 561.3K
- Earning Date
- FLYE 11-18-2025
- MGNX 11-04-2025
- Dividend Yield
- FLYE N/A
- MGNX N/A
- EPS Growth
- FLYE N/A
- MGNX N/A
- EPS
- FLYE N/A
- MGNX N/A
- Revenue
- FLYE $22,881,935.00
- MGNX $165,495,000.00
- Revenue This Year
- FLYE N/A
- MGNX N/A
- Revenue Next Year
- FLYE N/A
- MGNX N/A
- P/E Ratio
- FLYE N/A
- MGNX N/A
- Revenue Growth
- FLYE N/A
- MGNX 303.47
- 52 Week Low
- FLYE $0.51
- MGNX $0.99
- 52 Week High
- FLYE $8.30
- MGNX $5.10
- Technical
- Relative Strength Index (RSI)
- FLYE 31.29
- MGNX 44.10
- Support Level
- FLYE $0.64
- MGNX $1.69
- Resistance Level
- FLYE $0.72
- MGNX $1.83
- Average True Range (ATR)
- FLYE 0.06
- MGNX 0.10
- MACD
- FLYE 0.06
- MGNX -0.01
- Stochastic Oscillator
- FLYE 2.39
- MGNX 16.67
About FLYE Fly-E Group Inc. Common Stock
Fly-E Group Inc is an electric vehicle company that is principally engaged in designing, installing and selling smart electric motorcycles, electric bikes, electric scooters and related accessories under the brand Fly E-Bike. It also provides connectivity solutions and value-added services to their customers.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.